Duplicate discounts remain a significant problem for the 340B Drug Pricing Program. Reports from the Office of Inspector General (OIG) and the U.S. Government Accountability Office (GAO) have highlighted the problems, however, there is a simple solution that can eliminate duplicate discounts: Convert 340B purchase discounts to rebates.

Since 340B was created in 1992, covered entities only obtained the benefit of the program via an invoice discount effectuated through a wholesaler. Manufacturers and wholesalers have chargeback procedures to process these discounts. But today there is only one scenario that does not result in duplicate discounts: those 340B drugs dispensed by AIDS Drug Assistance Programs (ADAPs). And that’s because ADAPs receive 340B pricing in the form of a rebate. A 340B rebate will solve the duplicate discount problem, while providing benefits to all stakeholders. Most importantly, it would allow manufacturers and covered entities to work together in a transparent manner.

During this webinar, you’ll learn:

  • An understanding of Congress’ original goals for the 340B program
  • How intermediaries now threaten that vision - and the program itself
  • Why 340B rebates support all stakeholders

Featured Speaker

Jeremy Docken

Founder, CEO

Jeremy Docken is the founder and CEO of Kalderos, a technology company that is redefining how the business of healthcare performs. Jeremy is an expert in drug discount programs from regulatory and operational perspectives, the many issues around these programs and how the interplay between different discount programs from a financial, operational and political perspective lead to fraud, waste and abuse that Kalderos was created to correct. Jeremy’s expertise is relied on by government watchdogs, and he has met with the OIG and GAO on multiple occasions to share observations about what is going wrong with these programs based on real-world data contained within Kalderos' proprietary solutions.


Register now for this webinar